{
  "id": 14312830,
  "title": "Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says",
  "url": "https://urgent.news/2026/10/13/martin-shkreli-livestreamed-himself-violating-lifetime-pharma-ban-ftc",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T22:48:12.000Z",
  "source": {
    "name": "Ars Technica Health",
    "slug": "ars-technica-health",
    "url": "https://arstechnica.com/health/2026/10/martin-shkreli-livestreamed-himself-violating-lifetime-pharma-ban-ftc-says/"
  },
  "original_language": "en",
  "account": "Martin Shkreli, the former pharmaceutical executive notorious for dramatically increasing the price of a critical anti-parasitic medication by over 4,000% and subsequently serving a seven-year prison term for his fraudulent actions, has been prohibited from participating in the industry permanently since 2022. However, according to the Federal Trade Commission (FTC) and the attorneys general from seven states, Shkreli has persistently and significantly contravened this ban, allegedly engaging in stock trading in multiple drug companies and discussing the industry through live social media broadcasts. On Tuesday, the FTC and the seven states requested a federal judge to deem Shkreli in contempt of court for these alleged infractions. The states involved encompass New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia, the same jurisdictions that joined the FTC in initiating legal proceedings against Shkreli in 2020 concerning a complex anti-competitive scheme involving the anti-parasitic drug, Daraprim, which skyrocketed its price from $17.50 per pill to $750 per pill in an instant, simultaneously obstructing the entry of generic competitors into the market.",
  "summary": "\"I can always find a couple of biotech stocks to smoke,\" Shkreli said in a livestream.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 5,
    "also_reported_by": [
      {
        "outlet": "FTC Competition",
        "title": "FTC, States Ask Federal Court to Hold Martin Shkreli in Contempt for Allegedly Violating Lifetime Ban from Pharmaceutical Industry",
        "url": "https://urgent.news/2026/10/13/ftc-states-ask-federal-court-to-hold-martin-shkreli-in-contempt-for",
        "published": "2026-10-13T12:00:00.000Z"
      },
      {
        "outlet": "The Hill",
        "title": "FTC: 'Pharma bro' Shkreli violated lifetime industry ban, should be held in contempt",
        "url": "https://urgent.news/2026/10/13/ftc-pharma-bro-shkreli-violated-lifetime-industry-ban-should-be-held",
        "published": "2026-10-13T17:05:31.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "FTC accuses Martin Shkreli of violating lifetime pharma ban",
        "url": "https://urgent.news/2026/10/13/ftc-accuses-martin-shkreli-of-violating-lifetime-pharma-ban",
        "published": "2026-10-13T19:04:39.000Z"
      },
      {
        "outlet": "Ars Technica",
        "title": "Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says",
        "url": "https://urgent.news/2026/10/13/martin-shkreli-livestreamed-himself-violating-lifetime-pharma-ban-ftc-14321394",
        "published": "2026-10-13T22:48:12.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}